KR20130115393A - 경구 투여용 고형 제제 - Google Patents

경구 투여용 고형 제제 Download PDF

Info

Publication number
KR20130115393A
KR20130115393A KR1020137025458A KR20137025458A KR20130115393A KR 20130115393 A KR20130115393 A KR 20130115393A KR 1020137025458 A KR1020137025458 A KR 1020137025458A KR 20137025458 A KR20137025458 A KR 20137025458A KR 20130115393 A KR20130115393 A KR 20130115393A
Authority
KR
South Korea
Prior art keywords
tablets
tablet
weight
starch
solid preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137025458A
Other languages
English (en)
Korean (ko)
Inventor
야스아키 오오바야시
아키코 오오카와
아츠코 하다마
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Publication of KR20130115393A publication Critical patent/KR20130115393A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137025458A 2008-02-21 2009-02-20 경구 투여용 고형 제제 Ceased KR20130115393A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2008-040696 2008-02-21
JP2008040696 2008-02-21
JP2008284685 2008-11-05
JPJP-P-2008-284685 2008-11-05
PCT/JP2009/053039 WO2009104739A1 (ja) 2008-02-21 2009-02-20 経口投与用固形製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107020649A Division KR101563383B1 (ko) 2008-02-21 2009-02-20 경구 투여용 고형 제제

Publications (1)

Publication Number Publication Date
KR20130115393A true KR20130115393A (ko) 2013-10-21

Family

ID=40985616

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107020649A Active KR101563383B1 (ko) 2008-02-21 2009-02-20 경구 투여용 고형 제제
KR1020137025458A Ceased KR20130115393A (ko) 2008-02-21 2009-02-20 경구 투여용 고형 제제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020107020649A Active KR101563383B1 (ko) 2008-02-21 2009-02-20 경구 투여용 고형 제제

Country Status (9)

Country Link
US (1) US20110059980A1 (enExample)
EP (1) EP2251011B1 (enExample)
JP (2) JP4409630B2 (enExample)
KR (2) KR101563383B1 (enExample)
CN (1) CN102014909B (enExample)
AT (1) ATE552002T1 (enExample)
CA (1) CA2715760C (enExample)
EA (1) EA023972B1 (enExample)
WO (1) WO2009104739A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US20110059980A1 (en) * 2008-02-21 2011-03-10 Yasuaki Oobayashi Solid preparation for oral administration
NZ590852A (en) 2008-07-16 2013-03-28 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands trans-1{ 4-[2-[4-(2,3-dichlorophenyl)-piperizin-1-yl]-ethyl]-cyclohexyl} -3,3-dimethyl-urea also known as cariprazine
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
EP3231418A1 (en) * 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
JP7020688B2 (ja) * 2016-06-28 2022-02-16 株式会社日本抗菌総合研究所 賦形剤及び錠剤
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107970217A (zh) * 2016-10-25 2018-05-01 浙江京新药业股份有限公司 卡利拉嗪口腔崩解片及其制备方法
CN108261394B (zh) * 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11273156B2 (en) * 2018-11-20 2022-03-15 Aurobindo Pharma Ltd Stable cariprazine formulations for oral use
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
EP4193987A4 (en) * 2020-08-06 2024-08-21 SK Biopharmaceuticals Co., Ltd. SOLID ORAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND PROCESS FOR ITS PREPARATION
CN118526462B (zh) * 2024-07-25 2024-11-15 山东则正医药技术有限公司 不同规格溶出行为相似的盐酸卡利拉嗪口崩片及制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666911A (en) * 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
GB8802622D0 (en) * 1988-02-05 1988-03-02 Glaxo Group Ltd Chemical compound
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2186371A1 (en) * 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
PL345166A1 (en) * 1998-06-30 2001-12-03 Zeria Pharm Co Ltd N-phenyl-n'-phenylpropylpiperazine derivatives and process for the preparation thereof
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
JP4276839B2 (ja) * 2001-02-27 2009-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
US6566550B2 (en) * 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
US6919342B2 (en) * 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
MY148643A (en) * 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
UA97847C2 (ru) * 2007-08-01 2012-03-26 Х. Луннбек А/С Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US20110059980A1 (en) * 2008-02-21 2011-03-10 Yasuaki Oobayashi Solid preparation for oral administration
NZ590852A (en) * 2008-07-16 2013-03-28 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands trans-1{ 4-[2-[4-(2,3-dichlorophenyl)-piperizin-1-yl]-ethyl]-cyclohexyl} -3,3-dimethyl-urea also known as cariprazine
HU230067B1 (hu) * 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives

Also Published As

Publication number Publication date
EP2251011B1 (en) 2012-04-04
ATE552002T1 (de) 2012-04-15
JPWO2009104739A1 (ja) 2011-06-23
CA2715760C (en) 2017-06-13
EP2251011A4 (en) 2011-03-02
WO2009104739A1 (ja) 2009-08-27
CN102014909A (zh) 2011-04-13
CA2715760A1 (en) 2009-08-27
EA023972B1 (ru) 2016-08-31
KR20100117676A (ko) 2010-11-03
EP2251011A1 (en) 2010-11-17
EA201001334A1 (ru) 2011-06-30
JP4409630B2 (ja) 2010-02-03
KR101563383B1 (ko) 2015-10-26
JP2010132654A (ja) 2010-06-17
US20110059980A1 (en) 2011-03-10
CN102014909B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
KR101563383B1 (ko) 경구 투여용 고형 제제
US20090281136A1 (en) Prasugrel pharmaceutical formulations
EP1810676B1 (en) Levetiracetam formulations and methods for their manufacture
EP2934488B1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
JP4446177B2 (ja) 耐湿性口腔内崩壊錠の製造方法
WO2011074660A1 (ja) 溶出安定性製剤
KR20160002177A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
JP5844574B2 (ja) ピタバスタチンを含有する安定化された薬物組成物
JPH1067657A (ja) マルチプルユニット型持続性製剤
WO2010027101A1 (ja) 医療用固形製剤
JP6106359B2 (ja) ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
KR102044734B1 (ko) 캡슐 제형
JP5774308B2 (ja) 水溶性ビノレルビン塩の安定な医薬組成物
KR102102462B1 (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
JP2020083887A (ja) アジルサルタンを含有する錠剤
CA2927437C (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
JP2025178961A (ja) エルトロンボパグ又はその薬学的に許容される塩を含む医薬組成物とその製造方法及び溶出遅延を抑制する方法
RU2266106C1 (ru) Способ получения антимикробного средства
CA3048968A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP2024077631A (ja) エルトロンボパグ オラミンを有効成分とする医薬組成物とその製造方法及び類縁物質の増加を抑制する方法
CN119564629A (zh) 一种美阿沙坦钾片及其制备方法
HK1106160A (en) Levetiracetam formulations and methods for their manufacture
WO2007049304A2 (en) Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
CN108236609A (zh) 一种gpr40激动剂药物组合物及其制备方法
JP2013119540A (ja) 固形医薬組成物およびその製造法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301